Ovary cancer
Conditions
Interventions
first group:Fasudil Hydrochloride Injection
second group:Standard chemotherapy agent and placebo
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: A total of 80 patients with recurrent ovarian cancer after pd clatinum-basehemotherapy, and the patients were randomly divided into 2 groups, with 40 patients in each group, and the age, pathological type, ECOG fitness score, prior chemotherapy plan and FIGO stage at initial treatment of patients in the two groups were completely matched. The inclusion criteria are as follows: 1. identified by genetic testing as A/A genotype; 2. aged 18-75 years; 3. ECOG score 0-1; 4. expected survival >= 3 months.
Exclusion criteria
Exclusion criteria: 1. Patients with hypotension and bleeding, such as cerebral hemorrhage; 2. Intracranial hemorrhage may occur: patients with bleeding aneurysms that have not been adequately hemostatic during surgery; 3. With uncontrollable pleural effusion, pericardial effusion or peritoneal effusion that requires repeated drainage 4. Giant aneurysm (diameter >= 2.5cm), vertebro-basal aneurysm; 5. With severe heart disease; 6. Patients with severe diabetes; 7. People with a history of mental illness before onset; 8. have severe liver and kidney insufficiency; 9. Persons with severe disturbance of consciousness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of treatment courses received;Overall survival;progression free survival;objective response rate;complete remission;partial remission; | — |
Secondary
| Measure | Time frame |
|---|---|
| blood pressure;heart rate; | — |
Countries
China
Contacts
Public ContactYingmei Wang
Outcome results
None listed